



Provincial Health Services Authority

PROTOCOL CODE: GIGAVCFT

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

DOCTOR'S ORDERS

Ht _____ cm Wt _____ kg BSA _____ m²

REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form

DATE: _____ **To be given:** _____ **Cycle #:** _____

Date of Previous Cycle: _____

- Delay treatment _____ week(s)
- CBC & Diff, Platelets, Creatinine** day of treatment

May proceed with doses as written if within 96 hours **ANC greater than or equal to 1.5 x 10⁹/L, Platelets greater than or equal to 100 x 10⁹/L, and Creatinine Clearance greater than or equal to 60 mL/minute**

Dose modification for: **Hematology** **Other Toxicity** _____

Proceed with treatment based on blood work from _____

PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.

dexamethasone 8 mg PO 30 to 60 minutes prior to chemotherapy
and **select ONE** of the following:

- | | |
|--------------------------|---|
| <input type="checkbox"/> | aprepitant 125 mg PO 30 to 60 minutes prior to chemotherapy
ondansetron 8 mg PO 30 to 60 minutes prior to chemotherapy |
| <input type="checkbox"/> | netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to chemotherapy |

Other: _____

PRE-HYDRATION: 1000 mL NS over 1 hour pre-CISplatin

CHEMOTHERAPY:

CISplatin 80 mg/m² x BSA = _____ mg

Dose Modification: _____ % = _____ mg/m² x BSA = _____ mg

IV in 500 mL NS with 20 mEq potassium chloride, 1 g magnesium sulfate, 30 g mannitol over 1 hour

Cycle 1 Only:

trastuzumab 8 mg/kg x _____ kg = _____ mg IV in 250 mL NS over 1 hour 30 minutes.

Observe for 1 hour post infusion**

Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190

Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date
trastuzumab		

acetaminophen 325 to 650 mg PO PRN for headache and rigors

fluorouracil 800 mg/m²/day x BSA = _____ mg/day for 5 days (total dose for each 5 day infusor = _____ mg over 120 h)

Dose Modification: _____ % = _____ mg/m²/day x BSA = _____ mg/day for 5 days (total dose for each 5 day infusor = _____ mg over 120 h)

IV in D5W to a total volume of 240 mL by continuous infusion at 2 mL/h via Baxter LV2 infusor.

(Total dose = 4000 mg/m² over 120 hours)

DOCTOR'S SIGNATURE:

SIGNATURE:

UC:

DATE:	To be given:	Cycle #:						
CHEMOTHERAPY:								
<input type="checkbox"/> Cycle 2								
trastuzumab 6 mg/kg x _____ kg = _____ mg IV in 250 mL NS over 1 hour every three weeks x _____ Cycle(s)								
Observe for 30 minutes post infusion**								
Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190								
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">Drug</th> <th style="width: 40%;">Brand (Pharmacist to complete. Please print.)</th> <th style="width: 40%;">Pharmacist Initial and Date</th> </tr> </thead> <tbody> <tr> <td>trastuzumab</td> <td></td> <td></td> </tr> </tbody> </table>			Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date	trastuzumab		
Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date						
trastuzumab								
<input type="checkbox"/> Cycle 3 and Subsequent:								
trastuzumab 6 mg/kg x _____ kg = _____ mg IV in 250 mL NS over 30 minutes every three weeks x _____ Cycle(s).								
Observe for 30 minutes post infusion**								
**Observation period not required after 3 treatments with no reaction.								
Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190								
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">Drug</th> <th style="width: 40%;">Brand (Pharmacist to complete. Please print.)</th> <th style="width: 40%;">Pharmacist Initial and Date</th> </tr> </thead> <tbody> <tr> <td>trastuzumab</td> <td></td> <td></td> </tr> </tbody> </table>			Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date	trastuzumab		
Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date						
trastuzumab								
acetaminophen 325 to 650 mg PO PRN for headache and rigors								
fluorouracil 800 mg/m ² /day x BSA = _____ mg/day for 5 days (total dose for each 5 day infusor = _____ mg over 120 h)								
<input type="checkbox"/> Dose Modification: _____ % = _____ mg/m ² /day x BSA = _____ mg/day for 5 days (total dose for each 5 day infusor = _____ mg over 120 h)								
IV in D5W to a total volume of 240 mL by continuous infusion at 2 mL/h via Baxter LV2 infusor.								
(Total dose = 4000 mg/m ² over 120 hours)								
DOCTOR'S SIGNATURE:		SIGNATURE:						
		UC:						



Provincial Health Services Authority

PROTOCOL CODE: GIGAVCFT

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

DATE:	
RETURN APPOINTMENT ORDERS	
<input type="checkbox"/> Return in three weeks for Doctor and Cycle _____ <input type="checkbox"/> Return in _____ weeks for Doctor and Cycle _____ <input type="checkbox"/> Last Cycle. Return in three weeks for GIGAVTR (to continue single agent trastuzumab)	
CBC & Diff, Platelets, Creatinine, Sodium, Potassium prior to each cycle If clinically Indicated: <input type="checkbox"/> Bilirubin <input type="checkbox"/> ALT <input type="checkbox"/> Alk Phos <input type="checkbox"/> MUGA scan or <input type="checkbox"/> Echocardiogram <input type="checkbox"/> ECG <input type="checkbox"/> CEA <input type="checkbox"/> CA 19-9 <input type="checkbox"/> Radiologic evaluation <input type="checkbox"/> INR weekly <input type="checkbox"/> INR prior to each cycle <input type="checkbox"/> Other tests: <input type="checkbox"/> Book for PICC assessment / insertion per Centre process <input type="checkbox"/> Book for IVAD insertion per Centre process <input type="checkbox"/> Weekly Nursing Assessment for (specify concern): _____ <input type="checkbox"/> Consults: <input type="checkbox"/> See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: